Abstract
Thirty children over the age of one month were treated with amikacin (BBK8), a new aminoglycoside derived from kanamycin A, with three intramuscular dosage schedules. Each group consisted of ten patients. The first received 7.5 mg/kg/12 hours, the second 7.5 mg/kg/24 hours and the third, 3.75 mg/kg/12 hours. The infections and the bacteria were similar in all three groups: pyelonephritis, abscesses of soft tissues, infected wounds, septicaemia, superinfected empyema, gastro-enteritis, chronic otitis media; the bacteria were E. coli, Klebsiella, Pseudomonas and Salmonella. A were sensitive by the Kirby-Bauer method, although two were resistant by dilution in Petri dish. Of the thirty patients, twenty four (80%) were cured. The schedule of 3.75 mg/kg/12 hours was as effective as the schedule of7.5 mg/kg/12 hours for infections such as pyelonephritis, superficial abcesses, contaminated wounds, gastro-enteritis and sepsis. The cases with infections localized in rather unaccessible sites required double the dose and strict drainage and cleanliness. Plasma levels with the administration of 3.75 mg/kg fluctuated between 8.3 and 12.6 mcg/ml; with 7.5 mg/kg they fluctuated between 8.6 and 13.1. The minimum inhibitory level (MIL) for the majority of the bacteria was 1.25 mcg/ml. No toxic reactions were observed.
Get full access to this article
View all access options for this article.